American Journal of Ophthalmology
Volume 141, Issue 1 , Pages 24-30, January 2006

Categorizing the Stage of Glaucoma From Pre-Diagnosis to End-Stage Disease

This project was previously presented as a poster at the Association for Research in Vision and Ophthalmology (ARVO) May 5–10, 2001.

  • Richard P. Mills, MD, MPH

      Affiliations

    • University of Washington, Seattle, Washington
  • ,
  • Donald L. Budenz, MD

      Affiliations

    • Bascom Palmer Eye Institute, Miami, Florida
  • ,
  • Paul P. Lee, MD, JD

      Affiliations

    • Duke University, Durham, North Carolina
  • ,
  • Robert J. Noecker, MD, MBA

      Affiliations

    • University of Pittsburgh, Pittsburgh, Pennsylvania
  • ,
  • John G. Walt, MBA

      Affiliations

    • Allergan, Inc, Irvine, California
    • Corresponding Author InformationInquiries to John Walt, MBA, Allergan, 2525 Dupont Drive, Irvine, CA 92623-9534; fax: 714-246-4241
  • ,
  • Lisa R. Siegartel, MPH

      Affiliations

    • Analytica International, New York, New York
  • ,
  • Stacy J. Evans, MD

      Affiliations

    • Analytica International, New York, New York
  • ,
  • John J. Doyle, DrPH

      Affiliations

    • Analytica International, New York, New York

Accepted 16 July 2005. published online 21 October 2005.

Purpose

To provide a reliable, comprehensive staging system to assess glaucoma stage in the absence of an universally accepted glaucoma staging system (GSS) on the basis of visual field results.

Design

Literature review and GSS adaptation.

Methods

After a review of published GSSs was conducted, the Bascom Palmer (Hodapp-Anderson-Parrish) GSS was selected as an appropriate platform for a retrospective GSS on the basis of visual fields. The system was modified by a panel of glaucoma specialists, and additional modifications were made after pilot testing to cover the full range of disease progression, from preglaucoma diagnosis to complete blindness; the ordered stages reflect the typical progression of glaucoma.

Results

The GSS is comprised of six ordered stages and is on the basis of the Humphrey visual field. The completed GSS was validated by reviewing patient charts from 12 US glaucoma centers.

Conclusions

The GSS allows accurate staging of 100% of glaucoma on the basis of visual fields and other data, enabling evaluation of disease progression and resource utilization at various glaucoma stages. Additionally, treatment costs may be assigned to determine cost-effectiveness of treatment. Research utilizing the GSS has found that cost of care increases with increasing disease severity. The GSS may be used as the basis for creating treatment guidelines, which have the potential to delay glaucoma progression and lower treatment costs.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study was supported by a research grant from Allergan, Inc., Irvine, California.

PII: S0002-9394(05)00817-2

doi:10.1016/j.ajo.2005.07.044

Refers to article:

  • The Stages of Glaucoma , 15 September 2005

    George L. Spaeth, M. Bruce Shields
    American Journal of Ophthalmology January 2006 (Vol. 141, Issue 1, Pages 147-148)

American Journal of Ophthalmology
Volume 141, Issue 1 , Pages 24-30, January 2006